6968-35-0

Usage

Uses

Used in Pharmaceutical Industry:
7-HYDROXY-1-INDANONE 97 is used as a building block for the synthesis of various pharmaceuticals and organic compounds. Its versatile chemical properties make it a valuable component in the development of new drugs and medications.
Used in Dye Industry:
7-HYDROXY-1-INDANONE 97 is used as a key intermediate in the production of dyes. Its unique chemical structure contributes to the color and properties of the dyes, making it an essential component in the dye manufacturing process.
Used in Perfume Industry:
7-HYDROXY-1-INDANONE 97 is used in the production of perfumes and other fragrances. Its ability to interact with other chemical compounds allows it to contribute to the overall scent profile of perfumes and other scented products.
Used in Specialty Chemicals Industry:
7-HYDROXY-1-INDANONE 97 is used as a key intermediate in the production of various specialty chemicals. Its versatility and unique chemical properties make it an important component in the development of new and innovative specialty chemicals for various applications.

InChI:InChI=1/C9H8O2/c10-7-3-1-2-6-4-5-8(11)9(6)7/h1-3,10H,4-5H2

Upstream product

• 491-37-2 2,3-dihydro-4H-1-benzopyran-4-one 
• 621-54-5 3-(3-hydroxyphenyl)-propanoic acid 
• 937-41-7 phenyl acrylate 
• 24552-27-0 3-chloropropionic acid phenyl ester 
• 533-75-5 2-hydroxy-2,4,6-cycloheptatrien-1-one 
• 1829-60-3 dimethyl 7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate 
• 38276-34-5 C₁₇H₁₆O₇ 
• 590-92-1 3-Bromopropionic acid 
• 108-95-2 phenol 
• 50663-21-3 (para-bromophenyl)-2-propenoate 
• 7446-70-0 aluminium trichloride 
• 40478-49-7 3-(3-methoxyphenyl)propanoyl chloride 
• 42710-26-9 phenyl 2-bromopropionate 
• 625-36-5 2-chloropropionyl chloride 

Downstream Products

• 108197-54-2 7-Hydroxy-2-[1-p-tolyl-meth-(Z)-ylidene]-indan-1-one 
• 125494-84-0 7-(phenylmethoxy)indan-1-one 
• 93747-67-2 7-allyloxyindan-1-one 
• 58350-01-9 7-hydroxy-1-aminoindan 
• 306999-74-6 C₁₅H₁₁NO₄ 
• 324534-56-7 4-phenyl-1H-indene 
• 1354558-51-2 (1S,2R)-epoxy-7'-phenylindane 
• 1354558-53-4 (1R,2R)-1-azido-7-phenyl-2,3-dihydro-1H-inden-2-ol 
• 1354558-55-6 (1R,2R)-1-amino-7-phenyl-2,3-dihydro-1H-inden-2-ol 
• 1354558-57-8 N₁,N₂-bis((1R,2R)-2-hydroxy-7-phenyl-2,3-dihydro-1H-inden-1-yl)oxalamide 
• 1354558-60-3 N₁,N₂-bis((1R,2R)-2-chloro-7-phenyl-2,3-dihydro-1H-inden-1-yl)oxalamide 
• 1354558-63-6 (3aR,3'aR,8aS,8'aS)-4,4'-diphenyl-8,8a,8',8'a-tetrahydro-3aH,3'aH-2,2'-biindeno[1,2-d]oxazole 
• 1354558-68-1 C₃₃H₂₅N₂O₂⁽¹⁺⁾*I^(1-) 
• 1354694-98-6 CF₃O₃S^(1-)*C₃₃H₂₅N₂O₂⁽¹⁺⁾ 

Relevant academic research and scientific papers

Total Synthesis of the Schisandraceae Nortriterpenoid Rubriflordilactone A

Full details of the total synthesis of the Schisandraceae nortriterpenoid natural product rubriflordilactone A are reported. Palladium- and cobalt-catalyzed polycyclizations were employed as key strategies to construct the central pentasubstituted arene from bromoendiyne and triyne precursors. This required the independent assembly of two AB ring aldehydes for combination with a common diyne component. A number of model systems were explored to investigate these two methodologies, and also to establish routes for the installation of the challenging benzopyran and butenolide rings.

Hindered N-oxides of cavity shaped molecules

1-Methoxy-5-oxo-11-azabenzo[b]fluorene and 1-methoxy--5,6-dihydro-12-azabenz[a]anthracene were synthesized. In both cases the N-oxide function was introduced by m-chloroperbenzoic acid oxidation. The steric effect is less significant in the investigated molecules than was suggested for similar systems.

Discovery of 2H-chromone-4-one based sulfonamide derivatives as potent retinoic acid receptor-related orphan receptor γt inverse agonists

Retinoic acid receptor related orphan receptor γt (RORγt), identified as the essential functional regulator of IL-17 producing Th17 cells, is an attractive drug target for treating autoimmune diseases. Starting from the reported GSK2981278 (Phase II), we structurally modified and synthesized a series of 2H-chromone-4-one based sulfonamide derivatives as novel RORγt inverse agonists, which significantly improved their human metabolic stabilities while maintaining a potent RORγt inverse agonist profile. Efforts in reducing the lipophilicity and improving the LLE values led to the discovery of c9, which demonstrated potent RORγt inverse agonistic activity and consistent metabolic stability. During in vivo studies, oral administration of compound c9 exhibited a robust and dose-dependent inhibition of IL-17A cytokine expression and significantly lessened the skin inflammatory symptoms in the mouse imiquimod-induced skin inflammation model. Docking analysis of the binding mode revealed that c9 can suitably occupy the active pocket, and the introduction of the morpholine pyridine group can interact with Leu396, His479, and Cys393. Thus, compound c9 was selected as a preclinical compound for treating Th17-driven autoimmune diseases.

Kinetic resolution of racemic benzofused alcohols catalysed by HMFO variants in presence of natural deep eutectic solvents

5-Hydroxymethylfurfural oxidase (HMFO) has demonstrated to be a useful biocatalyst for the selective oxidation of alcohols employing oxygen as mild oxidant with no requirement of expensive organic cofactors. This wild-type HMFO biocatalyst and an engineered thermostable variant have been tested in the kinetic resolution of different benzofused alcohols. The use of natural deep eutectic solvents was also explored in HMFO-catalysed oxidation of alcohols. The oxidation of racemic 1-indanol showed a higher conversion and selectivity in presence of 60% v/v of different NADES, especially for those containing carbohydrates. By choosing properly the biocatalyst and the NADES, good enantioselectivity values can be obtained, demonstrating the advantages of employing these neoteric solvents in biocatalysed processes.

ION CHANNEL ANTAGONISTS/BLOCKERS AND USES THEREOF

Provided are ion channel antagonists/blockers and uses thereof. Specifically, it provides the compounds of formula (I) or pharmaceutically acceptable salts, stereoisomers, solvates or prodrugs, preparation method therefor and application thereof. Definition of each group in the formula can be found in the specification for details. Provided is also pharmaceutical composition useful for treatment of heart disease and other ion channel related diseases.

Discovery of Chromane-6-Sulfonamide Derivative as a Potent, Selective, and Orally Available Novel Retinoic Acid Receptor-Related Orphan Receptor γt Inverse Agonist

Interleukin-17 (IL-17) is a proinflammatory cytokine that plays a dominant role in inflammation, autoimmunity, and host defense. RORγt is a key transcription factor mediating T helper 17 (Th17) cell differentiation and IL-17 production, which is able to activate CD8+ T cells and elicit antitumor efficacy. A series of sulfonamide derivatives as novel RORγt inverse agonists were designed and synthesized. Using GSK2981278 (phase II) as a starting point, we engineered structural modifications that significantly improved the activity and pharmacokinetic profile. In animal studies, oral administration of compound d3 showed a robust and dose-dependent inhibition of the IL-17A cytokine expression in a mouse imiquimod-induced skin inflammation model. Docking analysis of the binding mode revealed that the compound d3 occupied the active pocket suitably. Thus, compound d3 was selected as a clinical compound for the treatment of Th17-driven autoimmune diseases.

A class of GPR40 agonist compounds with amide structure, and uses thereof

The present invention relates to a class of amide compounds with a novel structure, and a pharmaceutical composition thereof, wherein the structure of the amide compound is represented by a general formula (I). According to the present invention, the amide compound (I) can regulate GPR40 activity, and can be used for GPR40 activity related diseases such as diabetes and metabolic syndrome. The formula I is defined in the specification.

A class of 2, 3 - dihydro - 1H - indenyl -4 - sulfonamide ROR γ regulator and its use (by machine translation)

The invention relates to a structure of formula (I) compound of formula or a stereoisomer thereof, tautomers or its pharmaceutically acceptable salt or solvate or prodrug, its preparation method, a pharmaceutical composition containing these modulators and their use in the treatment ROR γ-mediated inflammatory, metabolic and autoimmune disorders. (by machine translation)

Synthesis and Biological Evaluation of Tripartin, a Putative KDM4 Natural Product Inhibitor, and 1-Dichloromethylinden-1-ol Analogues

The natural product tripartin has been reported to inhibit the N-methyl-lysine histone demethylase KDM4A. A synthesis of tripartin starting from 3,5-dimethoxyphenylacrylic acid was developed, and the enantiomers were separated by chiral HPLC. We observed

Identification of novel 2-benzyl-1-indanone analogs as interleukin-5 inhibitors

A novel series of 2-benzyl-1-indanone analogs were investigated as IL-5 inhibitory activity. Among the synthesized compounds, 7-(cyclohexylmethoxy)-2-(4-hydroxybenzyl)-2,3-dihydro-1H-inden-1-one (7s, 100.0% inhibition at 30 μM, IC50 = 4.0 μM), and 7-(cyclohexylmethoxy)-2-(3-hydroxybenzyl)-2,3-dihydro-1H-inden-1-one (7t, 95.0% inhibition at 30 μM, IC50 = 6.0 μM) showed the best inhibitory activity against IL-5. The 2-benzyl-1-indanone analogs showed moderate to strong IL-5 inhibitory activity. Especially, hydroxyl (HBD/HBA) substituent at position 3 or 4 on phenyl ring B showed potent IL-5 inhibition. Additionally, the bulky hydrophobic cyclohexylmethoxy group at position 7 of the 1-indanone ring is favorable for the inhibitory activity.